{
  "id": 14587760,
  "title": "L&C Bio’s Re2O Secures UAE Import Approval, Opening Door to Middle East",
  "url": "https://urgent.news/2026/10/15/l-c-bios-re2o-secures-uae-import-approval-opening-door-to-middle-east",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-15T02:14:55.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=278857"
  },
  "original_language": "en",
  "account": "L&C Bio, a company specializing in regenerative medicine utilizing human tissue, has secured import approval for its product, Re2O, in the United Arab Emirates (UAE). This achievement positions the company for expansion into the Middle East, complementing its existing reach in Asia, South America, and North America. The UAE’s well-established medical tourism industry, evidenced by over 691,000 international medical tourists in Dubai alone in 2025, is expected to bolster the product's reception. L&C Bio plans to leverage this approval by establishing a robust network of medical professionals and expanding its sales base through collaborations with local entities. The company's flagship product, Re2O, is derived from human acellular dermal matrix (hADM), processed into fine particles that maintain the structural integrity of skin tissue. Recognizing the surging international demand, L&C Bio intends to double its Re2O production capacity to over 150,000 units monthly by year-end, with a new manufacturing facility in Dongtan planned for the future. Earlier this year, on Oct. 12, L&C Bio sealed an exclusive supply agreement with a U.S.-based partner, committing to meet substantial Re2O demand in the U.S. market starting in 2027, with the possibility of further structural expansion depending on market conditions. Success in overseas markets hinges on local professional adoption and a stable distribution network, and L&C Bio is strategically positioning itself for entry into the U.S. market post-approval by focusing on medical professional training and academic activities. The company's UAE import approval is seen as a crucial step towards realizing these expansion goals.",
  "summary": "L&C Bio, a company specializing in human tissue-based regenerative medicine, has secured entry into the United Arab Emirates (UAE) market, establishing a foothold for its expansion into the Middle East. Having already expanded into Asia, South America and North America, the company is accelerating i",
  "key_points": [
    "L&C Bio secures UAE import approval for Re2O, opening Middle East market.",
    "UAE's medical tourism industry of over 691,000 tourists in 2025 expected to boost reception.",
    "Company plans to double Re2O production capacity to 150,000 units monthly by year-end."
  ],
  "editors_take": "Securing regulatory clearance in the United Arab Emirates provides a vital gateway for L&C Bio to capitalize on the region's massive medical tourism industry and scale its global regenerative medicine footprint.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}